Drug Database · Clinicians

Amino acids + Electrolytes + Glucose + Purified soy bean oil

Brands (2) Kabiven Central, Kabiven PeripheralShow all

Part of: Parenteral nutrition products (Drug Index, by product type)

Parenteral nutrition PH FDA category
Fixed-dose combination.

Rx · Prescription drug2 PH products PN kidney notes reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Parenteral nutrition: kidney notes

Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.

Brands: Kabiven Central · Kabiven Peripheral

Kidney notes: Kabiven Central

Kabiven Central (Fresenius Kabi AB) is a three-chamber bag of amino acids with electrolytes, glucose and a soybean-oil lipid emulsion for central-vein parenteral nutrition. The Philippine registration is the 2053 ml bag. It is a standard (not kidney-specific) formula that contains potassium, phosphate and magnesium.

Composition

Per presentation2053 ml bag
Amino acids (g)68
Nitrogen (g)10.8
Lipid (g)80
Glucose (g)200
Energy, total (kcal)1900
Energy, non-protein (kcal)1600
Sodium (mmol)64
Potassium (mmol)48
Magnesium (mmol)8
Calcium (mmol)4
Phosphate (mmol)20
Sulfate (mmol)8
Chloride (mmol)93
Acetate (mmol)78
  • Osmolality approximately 1230 mOsm/kg water; osmolarity approximately 1060 mOsmol/l (SmPC section 2).
  • Composition from the Swedish (EU) SmPC of Kabiven; the Philippine package insert was not available to compare.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Infusion rate should not exceed 2.6 ml/kg body weight per hour; maximum daily dose 40 ml/kg body weight per day (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
  • In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4). The bag already contains potassium and phosphate (see composition).
  • Give with caution in impaired lipid metabolism, which may occur in renal insufficiency, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
  • In malnourished patients, starting parenteral nutrition can precipitate fluid shifts with pulmonary edema and congestive heart failure (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A standard central three-chamber bag: it is suitable in kidney disease only with access to dialysis or hemofiltration when renal insufficiency is severe, and its 48 mmol potassium and 20 mmol phosphate per bag must be counted against serum levels. ESPEN does not support routine kidney-specific formulas; choose the bag by its calorie-to-protein ratio and monitor electrolytes closely.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Kidney notes: Kabiven Peripheral

Kabiven Peripheral (Fresenius Kabi AB) is a three-chamber bag of amino acids with electrolytes, glucose and a soybean-oil lipid emulsion with lower osmolarity, for peripheral or central infusion. Philippine registrations: 1440 ml and 1920 ml bags. It is a standard formula containing potassium and phosphate.

Composition

Per presentation1440 ml bag1920 ml bag
Amino acids (g)3445
Nitrogen (g)5.47.2
Lipid (g)5168
Glucose (g)97130
Energy, total, approx. (kcal)10001400
Energy, non-protein, approx. (kcal)9001200
Sodium (mmol)3243
Potassium (mmol)2432
Magnesium (mmol)45.3
Calcium (mmol)22.7
Phosphate (mmol)1114
Sulfate (mmol)45.3
Chloride (mmol)4762
Acetate (mmol)3952
  • Osmolality approximately 830 mOsm/kg water; osmolarity approximately 750 mOsmol/l (SmPC section 2).
  • Composition from the Swedish (EU) SmPC; the Philippine package insert was not available to compare.

Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.

Dose and rate limits

  • Infusion rate should not exceed 3.7 ml/kg body weight per hour; maximum daily dose 40 ml/kg body weight per day (SmPC 4.2).

Kidney notes

  • Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
  • In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4). The bag already contains potassium and phosphate (see composition).
  • Give with caution in impaired lipid metabolism, which may occur in renal insufficiency, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
  • In malnourished patients, starting parenteral nutrition can precipitate fluid shifts with pulmonary edema and congestive heart failure (SmPC 4.4).
  • Serum potassium and phosphorus may fall within 24 to 48 hours of starting parenteral nutrition in malnourished patients; monitor serum electrolytes and fluid balance regularly (SmPC 4.4).

How it fits the ESPEN 2021 kidney nutrition guideline

  • ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
  • ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
  • ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
  • ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
  • ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
  • ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
  • ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)

Bottom line

A standard peripheral three-chamber bag. In kidney disease, use it only with dialysis or hemofiltration available if renal insufficiency is severe, count its potassium and phosphate, and watch the volume (up to 40 ml/kg/day) in oliguric or dialysis patients.

renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed

Dosage forms

Philippines

  • Emulsion for iv infusion

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Amino acids + Electrolytes + Glucose + Purified soy bean oil as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Amino acids + Electrolytes + Glucose + Purified soy bean oil
Package insert
Kabiven CentralGlucose + Amino Acids + Electrolytes + Purified Soy Bean Oil
(see reverse for formulation) Emulsion for IV InfusionBiofine 3-Chamber Inner Bag Wrapped in a Plastic Overpouch x 2.053 L Box of 1's and 2's
Rx
Fresenius Kabi ABSweden
Fresenius Kabi Philippines, Inc.Importer: Fresenius Kabi Philippines Inc
DR-XY36260
Jul 14, 2029
Kabiven PeripheralGlucose + Amino Acids + Electrolytes + Purified Soy Bean Oil
(see reverse for formulation) Emulsion for IV InfusionBiofine 3 - Chamber Inner Bag Wrapped in a Plastic Overpouch x 1.44 L and 1.92 L (Box of 1's and 4's)
Rx
Fresenius Kabi ABSweden
Fresenius Kabi Philippines, Inc.
DR-XY36261
Jul 14, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  2. Fresenius Kabi. (2023). Kabiven emulsion for infusion [Summary of product characteristics, English version; text revised November 16, 2023]. Swedish Medical Products Agency. https://docetp.mpa.se/LMF/Kabiven%20emulsion%20for%20infusion%20ENG%20SmPC_09001bee807a42cb.pdf
  3. Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
  4. Fresenius Kabi. (2023). Kabiven Peripheral emulsion for infusion [Summary of product characteristics, English version; text revised November 16, 2023]. Swedish Medical Products Agency. https://docetp.mpa.se/LMF/Kabiven%20Perifer%20emulsion%20for%20infusion%20ENG%20SmPC_09001bee807a42ca.pdf

renalcarematters.com content: Parenteral nutrition kidney notes (Kabiven Central): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (Kabiven Peripheral): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .